| TITLE |
DATE |
| Ardea Biosciences to Present at Upcoming Investor Conferences |
15-Nov-2011 |
| Ardea Biosciences Provides Additional Positive Clinical Results for Lesinurad and Initial Clinical Results for RDEA3170 at the 2011 ACR/ARHP Annual Scientific Meeting |
7-Nov-2011 |
| Ardea Biosciences Reports Recent Accomplishments, Important Upcoming Events and Third Quarter 2011 Financial Results |
4-Nov-2011 |
| Ardea Biosciences to Present Data From Gout Program at the 2011 ACR/ARHP Annual Scientific Meeting |
19-Oct-2011 |
| Ardea Biosciences to Present at Upcoming Investor Conferences |
8-Sep-2011 |
| Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad |
7-Sep-2011 |
| Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference |
10-Aug-2011 |
| Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results |
5-Aug-2011 |
| Ardea Biosciences to Present at Upcoming Investor Conferences |
1-Jun-2011 |
| Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology |
25-May-2011 |
| Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting |
19-May-2011 |
| Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results |
9-May-2011 |
| Ardea Biosciences to Present at Two Upcoming Investor Conferences |
4-May-2011 |
| Ardea Biosciences to Present Additional Data From Completed Phase 2b Combination Study of Lesinurad (RDEA594) and Allopurinol at the Annual European Congress of Rheumatology |
25-Apr-2011 |
| Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results |
11-Mar-2011 |
| Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering |
23-Feb-2011 |
| Ardea Biosciences to Present at Two Upcoming Investor Conferences |
4-Feb-2011 |
| Ardea Biosciences Prices Public Offering of Common Stock |
20-Jan-2011 |
| Ardea Biosciences Announces Proposed Public Offering of Common Stock |
19-Jan-2011 |
| Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration |
10-Jan-2011 |
| Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients |
6-Jan-2011 |
| Ardea Biosciences to Present at Two Upcoming Investor Conferences |
12-Nov-2010 |
| Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
11-Nov-2010 |
| Ardea Biosciences Reports Recent Accomplishments and Third Quarter and Year-to-Date 2010 Financial Results |
9-Nov-2010 |
| Ardea Biosciences Announces Positive Results for RDEA594 in Combination with Febuxostat or Allopurinol in Gout Patients |
8-Nov-2010 |
| Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act |
2-Nov-2010 |
| Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference |
27-Oct-2010 |
| Ardea Biosciences to Present at Four Upcoming Investor Conferences |
13-Sep-2010 |
| Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2010 Financial Results |
6-Aug-2010 |
| Ardea Biosciences to Present at the Fifth Annual Piper Jaffray Europe Conference |
21-Jun-2010 |
| Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology |
18-Jun-2010 |
| Ardea Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference |
7-Jun-2010 |
| Ardea Biosciences to Present at Two Upcoming Investor Conferences |
14-May-2010 |
| Ardea Biosciences to Present Additional Data on Gout Program at the Annual European Congress of Rheumatology |
13-May-2010 |
| Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2010 Financial Results |
7-May-2010 |
| Ardea Biosciences to Present at Two Upcoming Investor Conferences |
6-May-2010 |
| Ardea Biosciences, Inc. Announces Appointment of Stephen R. Davis as Executive Vice President and Chief Operating Officer |
12-Apr-2010 |
| Ardea Biosciences, Inc. Announces Completion of Public Offering of Common Stock |
9-Apr-2010 |
| Ardea Biosciences, Inc. Announces Pricing of Public Offering of Common Stock |
6-Apr-2010 |
| Ardea Biosciences, Inc. Announces Proposed Public Offering of Common Stock |
5-Apr-2010 |
| Ardea Biosciences Announces Positive Top-Line Results from a Phase 2b Study of RDEA594 Given as Monotherapy in the Treatment of Hyperuricemia in Gout Patients |
31-Mar-2010 |
| Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance |
12-Mar-2010 |
| Ardea Biosciences to Present at Two Upcoming Investor Conferences |
5-Mar-2010 |
| Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors |
9-Feb-2010 |
| Ardea Biosciences to Present at the 12th Annual BIO CEO and Investor Conference |
5-Feb-2010 |
| Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat |
7-Jan-2010 |
| Ardea Biosciences Reports Positive Results from Combination of RDEA594 and Febuxostat |
1-Dec-2009 |
| Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference |
25-Nov-2009 |
| Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results |
6-Nov-2009 |
| Ardea Biosciences to Present at Three Upcoming Investor Conferences |
28-Oct-2009 |
| Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting |
19-Oct-2009 |
| Ardea Biosciences to Present Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting |
30-Sep-2009 |
| Ardea Biosciences to Present at Three Upcoming Investor Conferences |
16-Sep-2009 |
| Ardea Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 |
27-Aug-2009 |
| Ardea Biosciences Reports Recent Accomplishments and Announces Second Quarter and Year-to-Date 2009 Financial Results |
7-Aug-2009 |
| Ardea Biosciences Initiates Phase 2b Clinical Trial of RDEA594, Lead Product Candidate for the Treatment of Gout |
20-Jul-2009 |
| Ardea Biosciences to Present at the 4th Annual Piper Jaffray Europe Conference |
18-Jun-2009 |
| Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594 |
11-Jun-2009 |
| Ardea Biosciences to Present Preclinical and Phase 1 Data on its Lead Gout Product Candidate, RDEA594, at the Annual European Congress of Rheumatology |
18-May-2009 |
| Ardea Biosciences Reports Recent Accomplishments and First Quarter 2009 Financial Results |
8-May-2009 |
| Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer |
28-Apr-2009 |
| Ardea Biosciences Announces Positive Results from a Phase 1 Study of Lead Hyperuricemia and Gout Candidate, RDEA594 and a Phase 2a Study of RDEA594's Prodrug, RDEA806 |
20-Apr-2009 |
| Ardea Biosciences Announces Investor and Analyst Event Participants and Webcast Information |
13-Apr-2009 |
| Ardea Biosciences to Present Preclinical Multi-Drug Combination Synergy Data on its Lead MEK Inhibitor, RDEA119, at the American Association for Cancer Research 100th Annual Meeting |
20-Mar-2009 |
| Ardea Biosciences Announces Investor and Analyst Event |
16-Mar-2009 |
| Ardea Biosciences Reports Progress of Clinical Development Programs; Announces Fourth Quarter and Full-Year 2008 Financial Results and Provides 2009 Outlook and Financial Guidance |
13-Mar-2009 |
| Ardea Biosciences to Present at the Cowen & Co. 29th Annual Health Care Conference |
6-Mar-2009 |
| Ardea Biosciences Announces Positive Results from a Phase 1 Study of RDEA594 |
12-Jan-2009 |
| Ardea Biosciences Announces $30.6 Million Private Placement |
18-Dec-2008 |
| Ardea Biosciences to Present at the 20th Annual Piper Jaffray Healthcare Conference |
20-Nov-2008 |
| Ardea Biosciences Secures $8 Million Growth Capital Loan |
13-Nov-2008 |
| Ardea Biosciences Announces Progress of Clinical Development Programs and Reports Third Quarter and Year-to-Date 2008 Financial Results |
13-Nov-2008 |
| Ardea Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference and the Lazard Capital Markets 5th Annual Healthcare Conference |
29-Oct-2008 |
| Ardea Biosciences Presents Preliminary Data from a Phase 1 Study of RDEA594 at the 2008 ACR/ARHP Annual Scientific Meeting |
27-Oct-2008 |
| Ardea Biosciences Presents Additional Phase 2a and Preclinical Data on its Lead HIV Product Candidate, RDEA806, at the 48th Annual ICAAC/IDSA 46th Annual Meeting |
27-Oct-2008 |
| Ardea Biosciences Presents Preclinical Data on its Lead MEK Inhibitor, RDEA119, Demonstrating Synergy with Other Anti-Cancer Agents in Multiple Tumor Types |
24-Oct-2008 |
| Ardea Biosciences to Present Clinical Data on its Lead MEK Inhibitor, RDEA119, at the ASCO--NCI--EORTC 2nd Annual Meeting on Molecular Markers in Cancer |
24-Oct-2008 |
| Ardea Biosciences Awarded Composition of Matter Patent Covering RDEA806, Its Lead NNRTI for the Treatment of HIV |
20-Oct-2008 |
| Ardea Biosciences Initiates a Phase 1/2 Study of RDEA119, its Lead MEK Inhibitor, in Combination with Nexavar(R) (sorafenib) in Patients with Advanced Cancer |
16-Oct-2008 |
| Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting |
7-Oct-2008 |
| Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference |
17-Sep-2008 |
| Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting |
16-Sep-2008 |
| Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium |
11-Sep-2008 |
| Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting |
9-Sep-2008 |
| Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial |
21-Aug-2008 |
| Ardea Biosciences Announces Progress of Clinical Development Programs and Reports Second Quarter and Year-to-Date 2008 Financial Results |
14-Aug-2008 |
| Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference |
7-Aug-2008 |
| Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting |
28-Jul-2008 |
| Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference |
17-Jul-2008 |
| Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout |
9-Jul-2008 |
| Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing |
25-Jun-2008 |
| Craig Johnson Joins Ardea Biosciences' Board of Directors |
12-Jun-2008 |
| Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology |
11-Jun-2008 |
| Ardea to Present Data on Inflammation Programs at 2008 Annual European Congress of Rheumatology |
5-Jun-2008 |
| Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program |
22-May-2008 |
| Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis |
20-May-2008 |
| Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 |
19-May-2008 |
| Ardea Biosciences Announces Upcoming Corporate Meetings |
14-May-2008 |
| Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008 |
14-May-2008 |
| Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results |
9-May-2008 |
| Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors |
15-Apr-2008 |
| Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses |
14-Apr-2008 |
| Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences |
7-Apr-2008 |
| Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance |
24-Mar-2008 |
| Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load |
17-Mar-2008 |
| Ardea to Present at Cowen and Company's 28th Annual Health Care Conference |
11-Mar-2008 |
| Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego |
5-Mar-2008 |
| Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program |
26-Feb-2008 |
| Ardea Biosciences to Present at Roth Capital Partners' 20th Annual OC Growth Stock Conference |
12-Feb-2008 |
| Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus |
7-Feb-2008 |
| Ardea Biosciences Establishes Scientific Advisory Board for HIV Program |
4-Feb-2008 |
| Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections |
29-Jan-2008 |
| Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial |
31-Dec-2007 |
| Ardea Biosciences Announces $40 Million Private Placement |
20-Dec-2007 |
| Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference |
7-Dec-2007 |
| Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout |
28-Nov-2007 |
| Ardea Biosciences to Present at the Piper Jaffray 19th Annual Health Care Conference |
20-Nov-2007 |
| Ardea Biosciences to Present at the Lazard Capital Markets Fourth Annual Health Care Conference |
20-Nov-2007 |
| Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating And Financial Results |
14-Nov-2007 |
| New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties |
24-Oct-2007 |
| Ardea Biosciences to List on the NASDAQ Capital Market |
9-Oct-2007 |
| Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
8-Oct-2007 |
| Ardea Biosciences Announces Changes to Research Management |
5-Oct-2007 |
| Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients |
1-Oct-2007 |
| Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC |
19-Sep-2007 |
| RDEA806, A Potent, New HIV NNRTI With a High Genetic Barrier to Resistance and a Broad Spectrum of Activity, Introduced at 47th ICAAC |
18-Sep-2007 |
| Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 |
4-Sep-2007 |
| Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc. |
16-Aug-2007 |
| Ardea Biosciences, Inc. Reports Second Quarter 2007 Financial Results |
13-Aug-2007 |
| Ardea Biosciences, Inc. Stockholders Approve Company Proposals at July 27, 2007 Annual Meeting |
27-Jul-2007 |
| Ardea Biosciences, Inc. Announces Appointment of Patrick M. O'Connor as Senior Vice President of Research and Preclinical Development and Chief Scientific Officer |
26-Jul-2007 |
| Ardea Biosciences, Inc. Expands its Board of Directors |
15-Jun-2007 |
| Ardea Biosciences, Inc. Reports First Quarter 2007 Financial Results |
8-May-2007 |
| Ardea Biosciences, Inc. Reports 2006 Financial Results |
2-Apr-2007 |
| Ardea Biosciences, Inc. Announces Changes to Management Team |
28-Mar-2007 |
| Ardea Biosciences Announces New Corporate Headquarters, New Ticker Symbol, and Appointment of Key R&D Management Team |
12-Feb-2007 |
| Company Announces Acquisition of Research and Development Programs, |
22-Dec-2006 |
 |
